BTG1 (B-cell translocation gene 1) is a member of the BTG/TOB family of proteins, which are involved in regulating cellular processes such as proliferation, differentiation, and apoptosis. First identified in B-cell lymphomas, BTG1 acts as a transcriptional co-regulator and may interact with proteins like the CCR4-NOT complex to influence mRNA stability and degradation. Its expression is linked to cell cycle arrest and anti-proliferative effects, suggesting a tumor-suppressive role in certain cancers.
BTG1 antibodies are essential tools for studying its expression, localization, and function in both normal and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect BTG1 protein levels in tissues or cultured cells. Research has shown that BTG1 downregulation correlates with poor prognosis in cancers such as B-cell malignancies and gliomas, while its role in neuronal development and regeneration is also under investigation.
Commercial BTG1 antibodies vary by host species, clonality, and epitope specificity, requiring validation for experimental conditions. Understanding BTG1's regulatory networks and disease associations continues to advance through antibody-based studies, offering insights into therapeutic targets for cancer and neurological disorders.